Globally, there are currently 24 products in clinical development for the treatment of...
- Exploring efficiencies from eTMF with Cancer Research UK
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
US-Australia led research reveals promising drug for blood cancer
An international research collaboration between the US and Australia has revealed a new drug for the treatment of patients affected with high-risk leukemia.
Iovance and Cellectis agree research and license collaboration
US-based T cell-based cancer immunotherapies developer Iovance Biotherapeutics and clinical-stage biopharmaceutical firm Cellectis have signed a research collaboration and exclusive worldwide license agreement.
Nektar and Bristol-Myers Squibb expand clinical development programme
Nektar Therapeutics and Bristol-Myers Squibb Company have entered a revised strategic collaboration agreement to expand the clinical development programme for bempegaldesleukin (bempeg) plus Opdivo (nivolumab).
Veeva launches Vault Payments application to clinical research sites
Veeva Systems, a provider of Cloud-based software for the life sciences industry, has announced the launch of Veeva Vault Payments, a new add-on application for Veeva Vault CTMS.
Gene silencing therapy’s fast-track approval to expand treatment options for Huntington’s patients
Globally, there are currently 24 products in clinical development for the treatment of Huntington’s disease, which is a rare, inheritable neurodegenerative condition. Symptoms are typically noticed between the ages of 30 and 50 and include memory loss, anxiety, depression, and compulsive behaviors.
AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s
AtreMorine is a novel biopharmaceutical compound obtained by means of nondenaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.
Alzheimer’s Disease Prevention Plan
Dr Ramón Cacabelos, Professor and Chairman of Genomic Medicine, announces the implementation of a Preventive Program for Alzheimer’s disease at the International Center of Neurosciences and Genomic Medicine, Corunna, Spain.